User:Mr. Ibrahem/Sutimlimab

Sutimlimab, sold under the brand name Enjaymo, is a medication used to treat cold agglutinin disease (CAD). Specifically it is used to prevent the breakdown of red blood cells. It is given by gradual injection into a vein. People need to be vaccinated against encapsulated bacteria before it is started.

Common side effects include respiratory tract infections, diarrhea, joint pain, and peripheral swelling. Other side effects may include infections, infusion reactions, and autoimmune diseases. It is a monoclonal antibody that attaches to and blocks C1s.

Sutimlimab was approved for medical use in the United States and Europe in 2022. In the United States it costs about 280,000 USD per year for someone who weights 40 to 75 kg. It is not marketed in the United Kingdom.